Statins and non-alcoholic steatohepatitis

Metabolism: Clinical and Experimental

Volumn 66, Issue , 2017, Pages e1-e2

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

CARDIOVASCULAR MORTALITY; HUMAN; LETTER; MONOTHERAPY; MORBIDITY; NONALCOHOLIC FATTY LIVER; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84999766515     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.10.006     Document Type: Letter

References (8)

1. [1] Barb, D., Portillo-Sanchez, P., Cusi, K., Pharmacological management of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1183–1195.
2. [2] Kargiotis, K., Athyros, V.G., Giouleme, O., Katsiki, N., Katsiki, E., Anagnostis, P., et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 21 (2015), 7860–7868.
3. [3] Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R.M., Pipitone, R., Karja, V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 63 (2015), 705–712.
4. [4] Athyros, V.G., Tziomalos, K., Gossios, T.D., Griva, T., Anagnostis, P., Kargiotis, K., et al., GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376 (2010), 1916–1922.
5. [5] Tikkanen, M.J., Fayyad, R., Faergeman, O., Olsson, A.G., Wun, C.C., Laskey, R., et al., IDEAL Investigators, Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 168 (2013), 3846–3852.
6. [6] Athyros, V.G., Giouleme, O., Ganotakis, E.S., Elisaf, M., Tziomalos, K., Vassiliadis, T., et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 7 (2011), 796–805.
7. [7] Tziomalos, K., Athyros, V.G., Paschos, P., Karagiannis, A., Nonalcoholic fatty liver disease and statins. Metabolism 64 (2015), 1215–1223.
8. [8] Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65 (2016), 1109–1123.